A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma

CONCLUSIONS: Preoperative D+/-T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.PMID:38457288 | DOI:10.1158/1078-0432.CCR-23-3249

Source: Cell Research - March 8, 2024 Category: Cytology Authors: Chang Gon Kim Min Hee Hong Dahee Kim Brian Hyohyoung Lee Hyunwook Kim Chan-Young Ock Geoffrey Kelly Yoon Ji Bang Gamin Kim Jung Eun Lee Chaeyeon Kim Se-Heon Kim Hyun Jun Hong Young Min Park Nam Suk Sim Heejung Park Jin Woo Park Chang Geol Lee Kyung Hwan K Source Type: research